Agios Pharmaceuticals Inc
NASDAQ:AGIO 3:59:58 PM EDT
| Market Cap (Intraday) | 3.72B |
| Current PE | N/A |
| Forward PE | 2.34 |
| 2yr Forward PE | N/A |
| 10-Day MA | $58.87 |
| 50-Day MA | $56.06 |
| 200-Day MA | $46.86 |
Agios Pharmaceuticals Inc Stock, NASDAQ:AGIO
88 Sidney Street, 88 Sidney Street, Cambridge, Massachusetts 02139-4169
United States of America
Phone: +1.617.649.8600
Number of Employees: 562
Description
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.